TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1593412
Drug: Pulsated jet
Normalized name: ABG Pulsator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsated jet irrigator with saline solution
Study: 1593412
Drug: Syringe with
Normalized name: BD Syringe with Cannula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe with saline solution
Study: 30728061
Drug: Citrus Aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus Aurantium + Caffeine (CA + C) 100 mg of CA and 100 mg of C
Study: 27434441
Drug: Buprenorphine implants
Normalized name: buprenorphine Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine implants (80 mg, 4 implants)
Study: 27434441
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (8 mg/d or less) with placebo implants
Study: 22241281
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg amisulpride
Study: 22241281
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg aripiprazole
Study: 15569821
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg per day for 5 days
Study: 12572702
Drug: Low-dose spiral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spiral computed tomography (CT) screening
Study: 12572702
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy before surgery
Study: 10469812
Drug: Prescription for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for 2 quarts of ORS filled for free at on-site pharmacy plus written instructions
Study: 1859751
Drug: Neostigmine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.1 mg kg‐1
Study: 1859751
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg kg‐1 (control group)
Study: 1859751
Drug: Doubling doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling doses of anticholinesterases
Study: 27989618
Drug: 45-mg sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45-mg sustained-release pelubiprofen
Study: 27989618
Drug: 75-mg sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg sustained-release eperisone hydrochloride
Study: 26390073
Drug: Control Auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Auricular Point Acupressure (sham treatment), n = 15
Study: 11473882
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (160 +/- 32 microg)
Study: 8037104
Drug: Enalapril, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 2.5 mg twice per day for 7 days (mean 6.1, range 2 to 7, median 7)
Study: 8037104
Drug: Enalapril, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 2.5 mg twice per day
Study: 17090988
Drug: Yakson therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yakson therapy (5 minutes of hand laying on the back and caressing the abdomen)
Study: 12576164
Drug: 3.0 mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg/min infusion of valproate sodium injection
Study: 12576164
Drug: 1.5 mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg/min infusion of valproate sodium injection
Study: 8913487
Drug: Atevirdine 600
Normalized name: Atevirdine
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine 600 mg three times a day for 12 weeks
Study: 28079755
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zeaxanthin per day
Study: 28079755
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zeaxanthin per day
Study: 23478167
Drug: Active RPSS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active RPSS with daily motor training
Study: 23478167
Drug: Sham RPSS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham RPSS with daily motor training
Study: 17156423
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise (one-hour supervised session twice a week and daily home exercises)
Study: 14660201
Drug: JTMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTMT with the left hand (L)
Study: 3533134
Drug: Nifedipine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (oral administration)
Study: 3533134
Drug: Ritodrine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (intravenous administration)
Study: 29976161
Drug: Serial IV
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial IV bolus (6 g loading dose with 2 g bolus every 2 h using a Springfusor® pump)
Study: 29976161
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (4 g loading dose with 1 g/hr. continuous infusion)
Study: 26882922
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg × 3)
Study: 26882922
Drug: Flurbiprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (50 mg × 3)
Study: 24253285
Drug: Norwalk virus
Normalized name: NORWALK VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwalk virus (dosage for secretor-positive blood group O or A)
Study: 24253285
Drug: Norwalk virus
Normalized name: NORWALK VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwalk virus (dosage for all secretor-positive persons)
Study: 20533760
Drug: Benzocaine lozenges
Normalized name: Benzocaine Lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine lozenges (8 mg), n = 123
Study: 20533760
Drug: Commercial pastilles
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial pastilles (8 mg), n = 123
Study: 21991892
Drug: Bronchodilator administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchodilator administration
Study: 12568852
Drug: Recombinant IL‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IL‐1 receptor antagonist
Study: 12568852
Drug: Anti‐IL‐1beta antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐IL‐1beta antibody
Study: 10867375
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with specific allergens (subcutaneous administration of the vaccine)
Study: 8623949
Drug: Large-dose fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose fentanyl anesthesia (LDFA)
Study: 8623949
Drug: Small-dose fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose fentanyl anesthesia (SDFA)
Study: 1423201
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of cyclophosphamide < 7.5 g/m2
Study: 1423201
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of cyclophosphamide > 7.5 g/m2
Study: 3804185
Drug: Omeprazole 5
Normalized name: esomeprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 5 mg daily
Study: 21753734
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no special treatments for the extraction socket)
Study: 9684190
Drug: Sublingual birch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual birch pollen extract
Study: 7979841
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluvastatin sodium once daily
Study: 7979841
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluvastatin sodium twice daily
Study: 29054679
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method using a custom tray border moulded with impression compound and silicone
Study: 27261067
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal vaccine
Study: 20461767
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue spray applied to the axillary fossa plus placement of closed suction drainage
Study: 18991123
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment with remission of maternal depression
Study: 9485226
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 20 ppm (n = 6)
Study: 21798883
Drug: Sifalimumab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifalimumab (0.3, 1, 3, 10 or 30 mg/kg)
Study: 25179088
Drug: Mouthwash solution
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash solution containing lysine (0.4%) and glycerol monolaurate (0.2%) (LGM)
Study: 25179088
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment for gastric eradication
Study: 25179088
Drug: Traditional drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drug gastric eradication and teeth cleaning (TC)
Study: 25179088
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of oral infection
Study: 8607501
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily plus metronidazole 250 mg four times daily
Study: 8607501
Drug: Methylprednisolone 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 0.7 mg/kg/day with variable tapering to 40 mg
Study: 6129858
Drug: Clobazam (Frisium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (Frisium 20) administered in the morning for 28 days
Study: 6129858
Drug: Clobazam (Frisium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (Frisium 20) administered at night for 28 days
Study: 27071768
Drug: Pramlintide 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 30 or 60 µg
Study: 24501005
Drug: LDV 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 90 mg QD for 24 weeks
Study: 24501005
Drug: LDV 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 90 mg QD for 12 weeks
Study: 24501005
Drug: LDV 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 30 mg QD for 24 weeks
Study: 24501005
Drug: LDV 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 90 mg QD for 12 weeks in patients with vRVR
Study: 24501005
Drug: LDV 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 90 mg QD for 24 weeks in patients with vRVR
Study: 21822978
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus octreotide combination treatment post-TACE
Study: 21822978
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin plus octreotide treatment)
Study: 17150024
Drug: Natalizumab monotherapy
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab monotherapy 300 mg intravenous every 4 weeks
Study: 9663954
Drug: Long muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long muscle length (bout L)
Study: 3276280
Drug: Tranylcypromine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine (average dose, 40 mg/d)
Study: 3276280
Drug: Carbamazepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (average dose, 820 mg/d)
Study: 3276280
Drug: Trifluoperazine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluoperazine (average dose, 7.8 mg/d)
Study: 3276280
Drug: Alprazolam (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (average dose, 4.7 mg/d)
Study: 1827023
Drug: Intravenous isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous isradipine (0.5 mg, n = 10)
Study: 793779
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 mg to 3 mg daily)
Study: 793779
Drug: Frusemide (equipotent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (equipotent doses)
Study: 28392215
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene care programme (AOHCP) comprising a powered toothbrush, 0.2% chlorhexidine mouthrinse, toothpaste, and oral hygiene instruction
Study: 28392215
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene care programme (COHCP) comprising a manual toothbrush, toothpaste, and oral hygiene instruction
Study: 16287365
Drug: Runners Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runners Advantage (RA) creatine serum (5 ml containing 2.5 g of Cr)
Study: 9322568
Drug: Beta-carotene (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (90 mg/d for 3 weeks)
Study: 9322568
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg every other day for 10-12 years)
Study: 19917951
Drug: Daily text-message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text-message reminders for 6 weeks
Study: 15055205
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg/day orally
Study: 15055205
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg/day
Study: 1799473
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b maintenance therapy
Study: 25548141
Drug: Candesartan (+diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (+diuretics as needed)
Study: 10431100
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with pre-coseasonal treatment
Study: 10431100
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with preseasonal treatment
Study: 10431100
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with coseasonal treatment (highest maintenance dose)
Study: 2128047
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (placebo week)
Study: 375793
Drug: Physiologic (0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic (0.9%) saline solution
Study: 21414216
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care treatment for depression, smoking, and physical activity promotion
Study: 19568921
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids supplemented parenteral nutrition (0.8 g/kg/day soybean oil + 0.2 g/kg/day omega-3 FAs)
Study: 19568921
Drug: Standard soybean-oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard soybean-oil based fat (1.0 g/kg/day omega-6 FAs)
Study: 17760535
Drug: Early-loaded dental
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early-loaded dental implants (N = 18)
Study: 17760535
Drug: Delayed-loaded dental
Normalized name: Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-loaded dental implants (N = 16)
Study: 6107116
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg three times daily
Study: 6107116
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 capsule three times daily
Study: 20606118
Drug: Aggressive decongestion
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive decongestion (higher doses of loop diuretics, greater fluid loss)
Study: 18284263
Drug: Probiotics (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (various strains including Lactobacillus rhamnosus GG) administered for 1 or 2 months
Study: 18284263
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus rhamnosus GG) administered perinatally to mothers and to infants for the first 6 months
Study: 18284263
Drug: L. acidophilus
Normalized name: L. acidophilus/L.bulgaricus ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. acidophilus administered for the first 6 months of life
Study: 14738128
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a 2% sodium fluoride gel and exposure to the oral cavity (F)
Study: 14738128
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to the oral cavity (C+)
Study: 8984570
Drug: rubber‐band ligature,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rubber‐band ligature, anal dilator and Kamillosan ointment
Study: 1773325
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with continuous infusion of epidural fentanyl
Study: 25481454
Drug: Healthy School
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy School and Drugs (HSD) program
Study: 22916320
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (KRG) 4.5 g/d for 12 weeks
Study: 24906384
Drug: 131I therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I therapy
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (50 mg alternate days)
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (50 mg daily)
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (100 mg alternate days)
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (100 mg daily)
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (200 mg daily)
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (300 mg daily)
Study: 28570723
Drug: Oral X-82
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral X-82 (all doses)
Study: 25065017
Drug: Family-aided Assertive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-aided Assertive Community Treatment (FACT)
Study: 23278647
Drug: Surinabant 20
Normalized name: Surinabant
DrugBank: Surinabant (DB13070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surinabant 20 mg
Study: 23278647
Drug: Surinabant 60
Normalized name: Surinabant
DrugBank: Surinabant (DB13070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surinabant 60 mg
Study: 23278647
Drug: Surinabant 5
Normalized name: Surinabant
DrugBank: Surinabant (DB13070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surinabant 5 mg
Study: 9349067
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg with droperidol 0.75 mg
Study: 9349067
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg with droperidol 1.25 mg
Study: 8455964
Drug: Outpatient group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient group cognitive therapy
Study: 8455964
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy in combination with relaxation training
Study: 8455964
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment conditions (including WL)
Study: 3816293
Drug: Mequitazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine (5 mg twice daily for 14 days)
Study: 17367953
Drug: Manual-guided group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-guided group behavioral therapies (Cognitive Behavioral Therapy or Twelve Step Facilitation)
Study: 12003439
Drug: Elk velvet
Normalized name: velvet grass pollen extract
DrugBank: Holcus lanatus pollen (DB10395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elk velvet antler (2 capsules, 215 mg each)
Study: 12003439
Drug: Elk velvet
Normalized name: velvet grass pollen extract
DrugBank: Holcus lanatus pollen (DB10395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elk velvet antler (4 capsules, 215 mg each)
Study: 12003439
Drug: Elk velvet
Normalized name: velvet grass pollen extract
DrugBank: Holcus lanatus pollen (DB10395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elk velvet antler (6 capsules, 215 mg each)
Study: 7614523
Drug: Nabumetone, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone, 1,000 mg once daily
Study: 2203262
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg in the morning and 250 mg in the evening
Study: 3914703
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg twice a day
Study: 29231431
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (5 mg once daily for 3 months)
Study: 25169119
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (CRT) - cisplatin and 5-fluorouracil with 45 Gy of concurrent radiotherapy